The IL-23/Th 17 pathway in spondyloarthritis: the royal road?

Joint Bone Spine. 2015 Jan;82(1):1-4. doi: 10.1016/j.jbspin.2014.08.003. Epub 2014 Sep 22.

Authors

Daniel Wendling¹, Xavier Guillot², Clément Prati²

Affiliations

¹ Service de rhumatologie, CHRU de Besançon, université de Franche-Comté, boulevard Fleming, 25030 Besançon, France. Electronic address: dwendling@chu-besancon.fr.
² Service de rhumatologie, CHRU de Besançon, université de Franche-Comté, boulevard Fleming, 25030 Besançon, France.

PMID: 25245641
DOI: 10.1016/j.jbspin.2014.08.003

No abstract available

Keywords: Interleukin-17; Interleukin-23; Pathophysiology; Spondyloarthritis; Treatment.

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal / therapeutic use
Humans
Interleukin-17 / biosynthesis
Interleukin-17 / immunology*
Interleukin-23 / immunology*
Polymorphism, Single Nucleotide
Spondylarthritis / blood
Spondylarthritis / drug therapy
Spondylarthritis / genetics
Spondylarthritis / immunology*
Th17 Cells / immunology*

Substances

Antibodies, Monoclonal
Interleukin-17
Interleukin-23